A. Nichols, L. Richards, J. Behrle
Mar 14, 2013
Citations
0
Influential Citations
8
Citations
Quality indicators
Journal
Journal of Bioequivalence & Bioavailability
Abstract
Background: Desvenlafaxine (administered as desvenlafaxine succinate) is a serotonin-norepinephrine reuptake inhibitor approved for treatment of major depressive disorder. Because it is primarily eliminated unchanged by renal excretion, it is important to characterize the effect of patient factors, such as age and sex that may influence renal clearance. Methods: The pharmacokinetics, safety, and tolerability of a single oral dose of desvenlafaxine were assessed in healthy adults stratified by age (young, 18-45 years; elderly, 65-75; very old, >75) and sex in an open-label, inpatient trial. Results: Desvenlafaxine was generally well tolerated and was slowly absorbed in all age groups. Mean values for peak plasma concentration (C max ) for women exceeded those of men (P 75 years.